Ardea Biosciences (RDEA) Posts Q3 Loss of $0.13, Tops Views
More News related to RDEA
- Ardea Biosciences Announces Appointment of Felix J. Baker, Ph.D. to Board of Directors
- Ardea Biosciences to Present at the 12th Annual BIO CEO and Investor Conference
- Soleil Securities Initiates Coverage on Ardea Biosciences (RDEA) with a Buy
- Ardea Biosciences Reports Positive Results for RDEA594, its Lead Product Candidate for Gout, in Combination with Allopurinol or Febuxostat
- Jefferies & Co Initiates/Resumes Coverage on Pharma/Biotechnology Stocks
More News related to Earnings
- HNI Corporation (HNI) Tops Q1 EPS by 2c; Revs Light
- Team Health (TMH) Reports Mixed Q4 Results
- Baidu (BIDU) Blows the Lid Off Q4, Shares Jump
- Aspen Insurance (AHL) Posts Q4 adj.-EPS of $1.44, Tops Views
- Acadia Realty Trust (AKR) Misses Q4 FFO by 1c; Guides Below for FY10
Ardea Biosciences, Inc. (NASDAQ: RDEA) reports Q3 EPS of $0.13, versus the analyst estimate of ($0.53). Revenue for the quarter was $ million, which compares to the estimate of $3.51 million.
Related Categories
EarningsStocks Mentioned
+0.04Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
